Skip to Main Content

Yale a Site for New COVID-19 NIAID Study

June 08, 2020
by Julie Parry

Yale School of Medicine (YSM) is one of 10 sites across the U.S.A. participating in the National Institute of Allergy and Infectious Diseases’s (NIAID) study, “Immunophenotyping assessment in a COVID-19 Cohort (IMPACC).” The IMPACC study recruits patients hospitalized with COVID-19 as part of an in-depth investigation of immune responses to the SARS-CoV2 virus. Enrollment began in May.

Study participants will be followed for a year post-hospitalization to gauge recovery, whether they develop immunity to the virus, and to define critical elements of immunity associated with their clinical outcome.

Albert C. Shaw, MD, PhD, Professor of Medicine (infectious diseases) is Yale’s clinical principal investigator (PI) with Ruth R. Montgomery, PhD, Professor of Medicine (Rheumatology) directing the Immunophenotyping core.

The award is an administrative supplement to the Human Immunology U19, “Systems Immune Profiling of Divergent Responses to Infection” (PIs Ruth Montgomery, PhD, and David A. Hafler, MD, FANA, William S. and Lois Stiles Edgerly Professor and chair, Department of Neurology and professor of Immunobiology).

The IMPACC project involves expertise across YSM and is a collaboration with the Yale COVID-19 Biorepository, including the following faculty and members of their respective labs:

Submitted by Julie Parry on June 08, 2020